AAPL315.94-4.03 (-1.26%) ▼|ABBV251.02-5.44 (-2.12%) ▼|ABT105.72-2.61 (-2.41%) ▼|ACN178.68-8.05 (-4.31%) ▼|ADBE257.90-8.61 (-3.23%) ▼|AMAT470.10+15.39 (+3.38%) ▲|AMD508.05+30.48 (+6.38%) ▲|AMGN395.81-41.42 (-9.47%) ▼|AMT177.45+1.60 (+0.91%) ▲|AMZN257.21-1.30 (-0.50%) ▼|AVGO371.22+13.32 (+3.72%) ▲|AXP327.57+1.41 (+0.43%) ▲|BA215.19+2.94 (+1.39%) ▲|BAC62.65-0.04 (-0.06%) ▼|BKNG182.48-10.81 (-5.59%) ▼|BLK1,106.10-10.46 (-0.94%) ▼|BMY65.01-1.81 (-2.71%) ▼|BNY164.30-0.55 (-0.33%) ▼|BRK-B504.34-1.69 (-0.33%) ▼|C137.64-0.09 (-0.06%) ▼|CAT828.40+14.46 (+1.78%) ▲|CL88.20-0.57 (-0.64%) ▼|CMCSA26.15-0.35 (-1.30%) ▼|COF216.29-3.32 (-1.51%) ▼|COP135.48+1.22 (+0.91%) ▲|COST907.74-8.01 (-0.87%) ▼|CRM250.47-8.77 (-3.38%) ▼|CSCO109.38+0.18 (+0.16%) ▲|CVS95.76-0.98 (-1.02%) ▼|CVX211.10+2.50 (+1.20%) ▲|DE683.73-9.80 (-1.41%) ▼|DHR205.78-1.88 (-0.91%) ▼|DIS104.56-0.75 (-0.71%) ▼|DUK121.17+0.95 (+0.79%) ▲|EMR153.67+0.85 (+0.56%) ▲|FDX318.85-3.67 (-1.14%) ▼|GD356.23-3.17 (-0.88%) ▼|GE338.87+1.75 (+0.52%) ▲|GEV961.23+19.28 (+2.05%) ▲|GILD146.16-4.84 (-3.20%) ▼|GM85.74-2.02 (-2.30%) ▼|GOOG335.45+0.14 (+0.04%) ▲|GOOGL338.53+0.07 (+0.02%) ▲|GS1,039.75+1.14 (+0.11%) ▲|HD317.30-3.75 (-1.17%) ▼|HON208.59-1.02 (-0.49%) ▼|IBM232.56-2.33 (-0.99%) ▼|INTC104.17+8.37 (+8.74%) ▲|INTU314.87-17.83 (-5.36%) ▼|ISRG350.35-16.35 (-4.46%) ▼|JNJ267.95-7.28 (-2.65%) ▼|JPM356.50-2.15 (-0.60%) ▼|KO87.91-0.16 (-0.18%) ▼|LIN470.26-7.31 (-1.53%) ▼|LLY1,119.32-30.04 (-2.61%) ▼|LMT540.95+15.67 (+2.98%) ▲|LOW202.44-2.02 (-0.99%) ▼|LRCX321.09+13.44 (+4.37%) ▲|MA568.31-10.91 (-1.88%) ▼|MCD255.65-0.04 (-0.02%) ▼|MDLZ60.97-0.31 (-0.51%) ▼|MDT91.82-2.35 (-2.50%) ▼|META616.72-0.05 (-0.01%) ▼|MMM166.26-2.30 (-1.36%) ▼|MO67.93-0.95 (-1.38%) ▼|MRK148.31-2.02 (-1.34%) ▼|MS218.05+0.33 (+0.15%) ▲|MSFT492.98-6.72 (-1.34%) ▼|MU1,019.25+2.66 (+0.26%) ▲|NEE84.09+0.66 (+0.79%) ▲|NFLX76.62-1.63 (-2.09%) ▼|NKE38.17-0.24 (-0.61%) ▼|NOW135.35-5.91 (-4.18%) ▼|NVDA226.66-3.70 (-1.61%) ▼|ORCL164.53+5.75 (+3.62%) ▲|PEP137.98+0.35 (+0.25%) ▲|PFE27.87-0.58 (-2.04%) ▼|PG144.69-1.75 (-1.20%) ▼|PLTR171.34-2.99 (-1.72%) ▼|PM184.68+2.15 (+1.18%) ▲|QCOM176.10+7.36 (+4.36%) ▲|RTX198.64-2.16 (-1.07%) ▼|SBUX102.87-1.60 (-1.53%) ▼|SCHW108.08-1.22 (-1.11%) ▼|SO89.01+0.90 (+1.02%) ▲|SPG209.60+0.16 (+0.08%) ▲|T25.72+0.04 (+0.17%) ▲|TMO600.83-12.95 (-2.11%) ▼|TMUS180.58-0.94 (-0.52%) ▼|TSLA366.87+12.79 (+3.61%) ▲|TXN259.90+1.46 (+0.56%) ▲|UBER73.45-2.32 (-3.06%) ▼|UNH395.99-1.15 (-0.29%) ▼|UNP289.92+0.30 (+0.10%) ▲|UPS101.22-1.07 (-1.05%) ▼|USB62.86-0.52 (-0.81%) ▼|V368.13-6.94 (-1.85%) ▼|VZ50.32+0.18 (+0.35%) ▲|WFC88.76-1.22 (-1.35%) ▼|WMT106.06-1.08 (-1.01%) ▼|XOM159.62+0.15 (+0.09%) ▲|AAPL315.94-4.03 (-1.26%) ▼|ABBV251.02-5.44 (-2.12%) ▼|ABT105.72-2.61 (-2.41%) ▼|ACN178.68-8.05 (-4.31%) ▼|ADBE257.90-8.61 (-3.23%) ▼|AMAT470.10+15.39 (+3.38%) ▲|AMD508.05+30.48 (+6.38%) ▲|AMGN395.81-41.42 (-9.47%) ▼|AMT177.45+1.60 (+0.91%) ▲|AMZN257.21-1.30 (-0.50%) ▼|AVGO371.22+13.32 (+3.72%) ▲|AXP327.57+1.41 (+0.43%) ▲|BA215.19+2.94 (+1.39%) ▲|BAC62.65-0.04 (-0.06%) ▼|BKNG182.48-10.81 (-5.59%) ▼|BLK1,106.10-10.46 (-0.94%) ▼|BMY65.01-1.81 (-2.71%) ▼|BNY164.30-0.55 (-0.33%) ▼|BRK-B504.34-1.69 (-0.33%) ▼|C137.64-0.09 (-0.06%) ▼|CAT828.40+14.46 (+1.78%) ▲|CL88.20-0.57 (-0.64%) ▼|CMCSA26.15-0.35 (-1.30%) ▼|COF216.29-3.32 (-1.51%) ▼|COP135.48+1.22 (+0.91%) ▲|COST907.74-8.01 (-0.87%) ▼|CRM250.47-8.77 (-3.38%) ▼|CSCO109.38+0.18 (+0.16%) ▲|CVS95.76-0.98 (-1.02%) ▼|CVX211.10+2.50 (+1.20%) ▲|DE683.73-9.80 (-1.41%) ▼|DHR205.78-1.88 (-0.91%) ▼|DIS104.56-0.75 (-0.71%) ▼|DUK121.17+0.95 (+0.79%) ▲|EMR153.67+0.85 (+0.56%) ▲|FDX318.85-3.67 (-1.14%) ▼|GD356.23-3.17 (-0.88%) ▼|GE338.87+1.75 (+0.52%) ▲|GEV961.23+19.28 (+2.05%) ▲|GILD146.16-4.84 (-3.20%) ▼|GM85.74-2.02 (-2.30%) ▼|GOOG335.45+0.14 (+0.04%) ▲|GOOGL338.53+0.07 (+0.02%) ▲|GS1,039.75+1.14 (+0.11%) ▲|HD317.30-3.75 (-1.17%) ▼|HON208.59-1.02 (-0.49%) ▼|IBM232.56-2.33 (-0.99%) ▼|INTC104.17+8.37 (+8.74%) ▲|INTU314.87-17.83 (-5.36%) ▼|ISRG350.35-16.35 (-4.46%) ▼|JNJ267.95-7.28 (-2.65%) ▼|JPM356.50-2.15 (-0.60%) ▼|KO87.91-0.16 (-0.18%) ▼|LIN470.26-7.31 (-1.53%) ▼|LLY1,119.32-30.04 (-2.61%) ▼|LMT540.95+15.67 (+2.98%) ▲|LOW202.44-2.02 (-0.99%) ▼|LRCX321.09+13.44 (+4.37%) ▲|MA568.31-10.91 (-1.88%) ▼|MCD255.65-0.04 (-0.02%) ▼|MDLZ60.97-0.31 (-0.51%) ▼|MDT91.82-2.35 (-2.50%) ▼|META616.72-0.05 (-0.01%) ▼|MMM166.26-2.30 (-1.36%) ▼|MO67.93-0.95 (-1.38%) ▼|MRK148.31-2.02 (-1.34%) ▼|MS218.05+0.33 (+0.15%) ▲|MSFT492.98-6.72 (-1.34%) ▼|MU1,019.25+2.66 (+0.26%) ▲|NEE84.09+0.66 (+0.79%) ▲|NFLX76.62-1.63 (-2.09%) ▼|NKE38.17-0.24 (-0.61%) ▼|NOW135.35-5.91 (-4.18%) ▼|NVDA226.66-3.70 (-1.61%) ▼|ORCL164.53+5.75 (+3.62%) ▲|PEP137.98+0.35 (+0.25%) ▲|PFE27.87-0.58 (-2.04%) ▼|PG144.69-1.75 (-1.20%) ▼|PLTR171.34-2.99 (-1.72%) ▼|PM184.68+2.15 (+1.18%) ▲|QCOM176.10+7.36 (+4.36%) ▲|RTX198.64-2.16 (-1.07%) ▼|SBUX102.87-1.60 (-1.53%) ▼|SCHW108.08-1.22 (-1.11%) ▼|SO89.01+0.90 (+1.02%) ▲|SPG209.60+0.16 (+0.08%) ▲|T25.72+0.04 (+0.17%) ▲|TMO600.83-12.95 (-2.11%) ▼|TMUS180.58-0.94 (-0.52%) ▼|TSLA366.87+12.79 (+3.61%) ▲|TXN259.90+1.46 (+0.56%) ▲|UBER73.45-2.32 (-3.06%) ▼|UNH395.99-1.15 (-0.29%) ▼|UNP289.92+0.30 (+0.10%) ▲|UPS101.22-1.07 (-1.05%) ▼|USB62.86-0.52 (-0.81%) ▼|V368.13-6.94 (-1.85%) ▼|VZ50.32+0.18 (+0.35%) ▲|WFC88.76-1.22 (-1.35%) ▼|WMT106.06-1.08 (-1.01%) ▼|XOM159.62+0.15 (+0.09%) ▲|
25.3 C
New York
Tuesday, September 8, 2026

Tag: diseases

newssourceFORcompanyinformationcontent1releasesmarket

OneMedNet Announces Additional $3.7 Million of Funding in Private Placement Transactions and Approximately $11 Million in Reductions in Liabilities

OneMedNet Announces Additional $3.7 Million of Funding in Private Placement Transactions and Approximately $11 Million in Reductions in Liabilities

SRPT STOCK LOSS: Sarepta Therapeutics, Inc. Shareholders are Alerted of Ongoing Securities Fraud Investigation — Contact BFA Law (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law about its ongoing securities fraud investigation.

TAG1 and PharmaLogic Announce Strategic Partnership to Advance Decentralized Lead-212 Generator Development

Collaboration accelerates TAG1's Pb-212 generator development and supports PharmaLogic's mission to scale radiopharmaceutical innovation. ST. LOUIS, June 24, 2025 /PRNewswire/ -- TAG1 Inc., a premier...

Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt...

BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray...

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

MINNEAPOLIS, June 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company...

Abcentra Announces Appointment of Dr. Peter Libby as a Board Member as it Enters Orticumab’s Phase 2b Trial (FORTIFY)

LOS ANGELES, June 24, 2025 /PRNewswire/ -- Abcentra LLC (Abcentra), a clinical stage biotechnology company specializing in coronary artery disease, today announced the appointment...

Sterotherapeutics Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating ST-002 for Cushing’s Syndrome

DOYLESTOWN, Pa., June 24, 2025 /PRNewswire/ -- Sterotherapeutics LLC, a clinical-stage biopharmaceutical company focused on rare endocrine diseases, today announced that the first patient...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...

EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial.

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to...

For media and investors only

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDiseases

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers